tbuckley/cabot-search huggingface dataset:
Delirium and Functional Recovery in Patients Discharged to Skilled Nursing Facilities After Hospitalization for Heart Failure
Authors: Caroline Madrigal, Jenny Kim, Lan Jiang, Jacob Lafo, Melanie Bozzay, Jennifer Primack, Stephen Correia, Sebhat Erqou, Wen-Chih Wu, James L. Rudolph
Journal: JAMA Network Open (2021)

<h3>Importance</h3> A substantial number of patients discharged to skilled nursing facilities (SNFs) after heart failure (HF) hospitalization experience regression in function or do not improve. Delirium is one of few modifiable risk factors in this patient population. Therefore, understanding the role of delirium in functional recovery may be useful for improving outcomes. <h3>Objective</h3> To assess the association of delirium with 30-day functional improvement in patients discharged to SNFs after HF hospitalization. <h3>Design, Setting, and Participants</h3> This retrospective cohort study included patients hospitalized for HF in 129 US Department of Veterans Affairs hospitals who were discharged to SNFs from October 1, 2010, to September 30, 2015. Data were analyzed from June 14 to December 18, 2020. <h3>Exposures</h3> Delirium, as determined by the Minimum Data Set (MDS) 3.0 Confusion Assessment Method, with dementia as a covariate, determined via<i>International Classification of Diseases, Ninth Revision (ICD-9)</i>coding. <h3>Main Outcomes and Measures</h3> The difference between admission and 30-day MDS 3.0 Activities of Daily Living (ADL) scores. <h3>Results</h3> A total of 20 495 patients (mean [SD] age, 78 [10.3] years; 78.9% White; and 97% male) were included in the analysis. Of the total sample, 882 patients (4.3%) had delirium on an SNF admission. The mean (SD) baseline ADL score on admission to SNF was significantly worse among patients with delirium than without (18.3 [4.7] vs 16.1 [5.2];<i>P</i> &lt; .001;<i>d</i> = 0.44.). On the 30-day repeated assessment, mean (SD) function (ADL scores) improved for both patients with delirium (0.6 [2.9]) and without delirium (1.8 [3.6]) (<i>P</i> &lt; .001;<i>d</i> = −0.38). In the multivariate adjusted model, delirium was associated with statistically significant lower ADL improvement (difference in ADL score, –1.07; 95% CI, –1.31 to –0.83;<i>P</i> &lt; .001). <h3>Conclusions and Relevance</h3> In this retrospective cohort study, patients with HF discharged to SNFs with delirium were less likely to show improvement in function compared with patients without delirium. Findings suggest a potential need to reexamine how and when health care professionals assess delirium in HF patients throughout their hospitalization and SNF course. Identifying and treating delirium for HF patients earlier in their care trajectory may play an important role in improving care and long-term functional outcomes in this population. Future research is warranted to further investigate the association between delirium and functional recovery for HF and other patient populations.
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies
Authors: B. Li, L. Gandhi, B. Besse, K. Jhaveri, J. Mazières, V. Boni, G. Shapiro, S. Waqar, S. Viteri, H. Park, D. Quinn, S. Stemmer, A. Cortot, M. Burkard, M. Scaltriti, H. Won, A. Lalani, L. Mcculloch, J. Bebchuk, F. Xu, R. Bryce, F. Meric-Bernstam, S. Piha-Paul, D. Solit, P. Janne
Journal: Journal of Thoracic Oncology (2021)
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response
Authors: Linda R. Duska, Virginia L. Filiaci, Joan L. Walker, Laura L. Holman, Emily K. Hill, Richard G. Moore, Kari L. Ring, Michael L. Pearl, Carolyn Y. Muller, Christina L. Kushnir, Heather A. Lankes, Megan I. Samuelson, Kelley S. Carrick, Anand Rajan, William H. Rodgers, Elise C. Kohn, Richard Piekarz, Kimberly K. Leslie
Journal: Clinical Cancer Research (2021)

Abstract Purpose: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in women with newly diagnosed endometrioid endometrial adenocarcinoma. Patients and Methods: This multisite, randomized, open-label surgical window study treated women intramuscularly on day 1 with 400 mg MPA. Entinostat given 5 mg by mouth on days 1, 8, and 15 was randomly assigned with equal probability. Surgery followed on days 21–24. Pretreatment and posttreatment tissue was assessed for PR H-scores, Ki-67 levels, and histologic response. Results: Fifty patients were accrued in 4 months; 22 and 20 participants had PR evaluable pretreatment and posttreatment slides in the MPA and MPA/entinostat arms, respectively. Median posttreatment PR H-scores were significantly lower than pretreatment H-scores in both arms but did not differ significantly (MPA: 247 vs. 27, MPA/entinostat 260 vs. 23, respectively, P = 0.87). Decreased Ki-67 was shown in 90% treated with MPA/entinostat compared with 68% treated with MPA alone (P = 0.13). Median PR H-score decreases were larger when Ki-67 was decreased (208) versus not decreased (45). The decrease in PR pretreatment versus posttreatment was associated with loss of Ki-67 nuclear staining, consistent with reduced cellular proliferation (P &amp;lt; 0.008). Conclusions: This surgical window trial rapidly accrued in a multisite setting and evaluated PR as its primary endpoint and Ki-67 as secondary endpoint. Despite no immediate effect of entinostat on PR in this short-term study, lessons learned can inform future window and treatment trials.
P09.12 SARS- CoV2 Impact in a Spanish Lung Cancer Cohort?
Authors: B. Nunez-Garcia, B. Nuñez-Garcia, A. Morito, M. Martínez, C. Traseira, R. Aguado, Y. Garitaonaindía, G. Visedo, F. Franco, V. Calvo, M. Provencio
Journal: Journal of Thoracic Oncology (2021)
Role of Allogeneic Reduced Intensity Conditioning Stem Cell Transplantation (RIC-SCT) in Older Patients with Acute Myeloid Leukemia (AML): Analysis of the ALFA-1200 Study
Authors: Claude Gardin, Cécile Pautas, Emilie Lemasle, Jean-Henri Bourhis, Lionel Ades, Jean-Pierre Marolleau, Jean Valère Malfuson, Lauris Gastaud, Emmanuel Raffoux, Isabel Cano, Thorsten Braun, Xavier Thomas, Sylvain Chantepie, Thomas Cluzeau, Stephane De Botton, Céline Berthon, Benjamin Papoular, Nicolas Boissel, Claude Preudhomme, Christine Terré, Gérard Socié, Mauricette Michallet, Ibrahim Yakoub-Agha, Karine Celli-Lebras, Herve Dombret
Journal: Blood (2017)
MA01.06 Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC
Authors: J. Bosch-Barrera, T. Moran, P. Estévez-García, P. Martin-Martorell, R. Sabatier, E. Nadal, E. Sais, E. Garralda, J.M. Lizcano, P. Muñoz Guardiola, H. Pérez-Montoyo, M. Yeste-Velasco, M. Cortal, C. Domènech, J. Alfon, J. Rodon
Journal: Journal of Thoracic Oncology (2021)
Trade-Offs and Toss-Ups: Making Revascularization Decisions in Carotid Artery Disease⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Daniel B. Mark, Manesh R. Patel, Kevin J. Anstrom
Journal: Journal of the American College of Cardiology (2011)
P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
Authors: C. Huang, Y. Wu, Y. Fan, J. Feng, H. Pan, L. Jiang, J. Yang, X. Li, X. Liu, J. Xiong, Y. Zhao, Y. Cheng, R. Ma, J. Wang, Y. Wang, Y. Liu, D. Lin, W. Shi, X. Lin
Journal: Journal of Thoracic Oncology (2021)
P09.16 Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). Real-Life Experience from Castile and Leon
Authors: S. Medina Valdivieso, C. Bayona Antón, L. Bellido Hernández, R. López-Castro, M. Fernández González, A. Reyes García, A. Díaz Serrano, B. Esteban Herrera, L. Sánchez Cousido, R. Gómez Bravo, E. Del Barco, E. Cuadrado-Albite, M. Vallejo-Pascual, B. De Frutos González, R. Escala Cornejo, T. García Peña, M. Rojas Piedra, S. De La Torre Lázaro, E. Escalera Martín, P. Diz Taín
Journal: Journal of Thoracic Oncology (2021)
‘Fat but powerful’ paradox: association of muscle power and adiposity markers with all-cause mortality in older adults from the EXERNET multicentre study
Authors: Julian Alcazar, David Navarrete-Villanueva, Asier Mañas, Alba Gómez-Cabello, Raquel Pedrero-Chamizo, Luis M Alegre, Gerardo Villa, Narcís Gusi, Marcela González-Gross, Jose Antonio Casajús, German Vicente-Rodriguez, Ignacio Ara
Journal: British Journal of Sports Medicine (2021)

Objectives To assess the influence of muscle power and adiposity on all-cause mortality risk and to evaluate the ‘fat but powerful’ (F+P) (or ‘fat but fit’) paradox in older adults. Methods A total of 2563 older adults (65‒91 years old) from the EXERNET multicentre study were included. Adiposity (body mass index (BMI), waist circumference, body fat percentage (BF%) and fat index), allometric and relative power (sit-to-stand muscle power test) and various covariates (age, sex, hypertension, smoking status and walking and sitting times per day) were registered at baseline. All-cause mortality was recorded during a median follow-up of 8.9 years. Participants were classified into four groups: lean and powerful (L+P), F+P, lean but weak and fat and weak (F+W). Cox proportional hazard regression models and adjusted HRs were calculated. Results According to BMI and waist circumference, all-cause mortality risk was reduced in the F+P (HR=0.55 and 0.63, p=0.044 and 0.049, respectively) and L+P (HR=0.57 and 0.58, p=0.043 and 0.025, respectively) groups. According to BF%, all-cause mortality decreased in the L+P group (HR=0.53; p=0.021), and a trend for a reduction was reported in the F+P group (HR=0.57; p=0.060). According to fat index, a survival benefit was only noted in the L+P group (HR=0.50; p=0.049). Higher levels of relative power reduced all-cause mortality risk among older people (HR=0.63 and 0.53, p=0.006 and 0.011, respectively). Conclusion Powerful older people exhibited a reduced 9-year all-cause mortality regardless of BMI, waist circumference and BF%. Obesity according to fat index blunted the survival benefits of being powerful.
Mid-term results off pump CABG for multivessel coronary disease in the drug-eluting stent era : A single clinical experience. The 73^ Annual Scientific Meeting of the Japanese Circulation Society
Authors: M Ochi, Yuji Maruyama, Shunichiro Sakamoto, Jiro Kurita, Makoto Shirakawa, Motoko Tanoue, Hajime Imura, Takashi Nitta, Kazuo Shimizu
Journal: Circulation (2009)
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
Authors: Anna M Varghese, Isha Singh, Rituraj Singh, Siddharth Kunte, Joanne F Chou, Marinela Capanu, Winston Wong, Maeve A Lowery, Zsofia K Stadler, Erin Salo-Mullen, Lily V Saadat, Alice C Wei, Marsha Reyngold, Olca Basturk, Ryma Benayed, Diana Mandelker, Christine A Iacobuzio-Donahue, David P Kelsen, Wungki Park, Kenneth H Yu, Eileen M O’Reilly
Journal: JNCI Journal of the National Cancer Institute (2021)

Recent evidence suggests a rising incidence of cancer in younger individuals. Herein, we report the epidemiologic, pathologic, and molecular characteristics of a patient cohort with early-onset pancreas cancer (EOPC).
HSR21-055: Treatment Patterns and Healthcare Resource Utilization in First-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma in Asian and Western Countries
Authors: Dena Jaffe, Marc DeCongelio, Joseph Gricar
Journal: Journal of the National Comprehensive Cancer Network (2021)

"HSR21-055: Treatment Patterns and Healthcare Resource Utilization in First-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma in Asian and Western Countries" published on 17 Mar 2021 by National Comprehensive Cancer Network.
P38.03 Immunohistochemical, Histologic and Genomic Characterisation of Early Stage Pulmonary Invasive Mucinous Adenocarcinoma
Authors: A. Tan, B. Ong, T. Koh, J. Chen, H.N. Oo, G. Lai, W. Tan, M. Ang, R. Kanesvaran, Q.S. Ng, A. Jain, T. Rajasekaran, W. Zhai, A. Skanderup, K.H.T. Lim, E. Tan, W. Lim, D. Tan, A. Takano
Journal: Journal of Thoracic Oncology (2021)
Serum sphingosine‐1‐phosphate is elevated in atopic dermatitis and associated with severity
Authors: Takashi Sakai, Nadine Herrmann, Laura Maintz, Tim Joachim Nümm, Thomas Welchowski, Ralf A. Claus, Markus H. Gräler, Thomas Bieber
Journal: Allergy (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2–Platelet‐Derived Growth Factor Receptor Beta–Yes‐Associated Protein Signaling Axis
Authors: Xin Luo, Nellie A. Campbell, Li He, Daniel R. O'Brien, Mark S. Singer, Hassan Lemjabbar‐Alaoui, Keun Soo Ahn, Rory Smoot, Michael S. Torbenson, Steven D. Rosen, Lewis R. Roberts
Journal: Hepatology (2021)

Existing therapeutic approaches to treat cholangiocarcinoma (CCA) have limited effectiveness, prompting further study to develop therapies for CCA. We report a mechanistic role for the heparan sulfate editing enzyme sulfatase 2 (SULF2) in CCA pathogenesis.In silico analysis revealed elevated SULF2 expression in human CCA samples, occurring partly through gain of SULF2 copy number. We examined the effects of knockdown or overexpression of SULF2 on tumor growth, chemoresistance, and signaling pathway activity in human CCA cell lines in vitro. Up-regulation of SULF2 in CCA leads to increased platelet-derived growth factor receptor beta (PDGFRβ)-Yes-associated protein (YAP) signaling activity, promoting tumor growth and chemotherapy resistance. To explore the utility of targeting SULF2 in the tumor microenvironment for CCA treatment, we tested an anti-SULF2 mouse monoclonal antibody, 5D5, in a mouse CCA xenograft model. Targeting SULF2 by monoclonal antibody 5D5 inhibited PDGFRβ-YAP signaling and tumor growth in the mouse xenograft model.These results suggest that SULF2 monoclonal antibody 5D5 or related agents may be potentially promising therapeutic agents in CCA.
Aortic Stenosis Progression, Cardiac Damage, and Survival
Authors: Li-Tan Yang, Amber Boler, Jose R. Medina-Inojosa, Christopher G. Scott, Matthew J. Maurer, Mackram F. Eleid, Maurice Enriquez-Sarano, Christophe Tribouilloy, Hector I. Michelena
Journal: JACC. Cardiovascular imaging (2021)
P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients
Authors: M. Riudavets, E. Auclin, F. Blanc-Durand, A. De Giglio, J.C. Benitez, L. Hendriks, R. Ferrara, C. Naltet, P. Lavaud, A. Gazzah, J. Adam, M. Naigeon, D. Planchard, N. Chaput, C. Caramella, B. Besse, L. Mezquita
Journal: Journal of Thoracic Oncology (2021)
Scholarly communications harmed by covid-19
Authors: Raj Bhopal, Alasdair P S Munro
Journal: BMJ (2021)

The covid-19 pandemic has accentuated an erosion in civility in academic discourse, leading to deep divisions being played out in social, mass, and professional media. 1 -4 Personal attacks have increased substantially, alongside accusations impugning the integrity and motivations of fellow researchers and clinicians. 1 -4 Such division is especially evident in non-academic routes of communication such as declarations, letters, petitions, and personal views.Many of the worst examples are occurring in public forums.
P43.03 Sphingomyelin Is a Candidate Predictor for Lung Adenocarcinoma Recurrence After Radical Surgery
Authors: Y. Takanashi, S. Sato, H. Tao, T. Kahyo, A. Kawase, H. Sugimura, K. Funai, N. Shiiya, M. Setou
Journal: Journal of Thoracic Oncology (2021)
FP06.04 Psychological Distress in Outpatients with Lymphoma, Lung and Breast Cancer during COVID-19 pandemic
Authors: A. Catino, D. Bafunno, C. Cormio, F. Romito, C. Minoia, G. Loseto, M. Dellino, G. Opinto, E. Silvestris, A. Guarini, F. Giotta, A. Latorre, M. Montrone, P. Pizzutilo, V. Longo, A. Mastrandrea, D. Ricci, F. Pesola, D. Galetta
Journal: Journal of Thoracic Oncology (2021)
P36.04 Molecular Prognostic Factors in Neuroendocrine Thymic Tumors: a Retrospective Multicentre Study
Authors: N. Daddi, M. Lugaresi, O. Mete, P. Ferolla, G. Darling, M. De Perrot, P. Solli, T.K. Waddell, P. Graziano, G. Cardillo, S. Keshavjee
Journal: Journal of Thoracic Oncology (2021)
Citrullinated vimentin mediates development and progression of lung fibrosis
Authors: Fu Jun Li, Ranu Surolia, Huashi Li, Zheng Wang, Gang Liu, Tejaswini Kulkarni, Adriana V. F. Massicano, James A. Mobley, Santanu Mondal, Joao A. de Andrade, Scott A. Coonrod, Paul R. Thompson, Keith Wille, Suzanne E. Lapi, Mohammad Athar, Victor J. Thannickal, A. Brent Carter, Veena B. Antony
Journal: Science Translational Medicine (2021)

Cd/CB-induced citrullinated vimentin promotes PAD2- and TLR4-dependent lung fibrosis.
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Authors: Peter Hillmen, Jeff Szer, Ilene Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean-Jacques Kiladjian, Carlos de Castro, Hisakazu Nishimori, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, Cedric Francois, Federico Grossi, Temitayo Ajayi, Antonio Risitano, Régis Peffault de Latour
Journal: New England Journal of Medicine (2021)

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegcetacoplan, a pegylated peptide targeting proximal complement protein C3, potentially inhibits both intravascular and extravascular hemolysis.
In vitro and in vivo correlation for lipid-based formulations: Current status and future perspectives
Authors: Yanping Huang, Qin Yu, Zhongjian Chen, Wei Wu, Quangang Zhu, Yi Lu
Journal: Acta Pharmaceutica Sinica B (2021)

Lipid-based formulations (LBFs) have demonstrated a great potential in enhancing the oral absorption of poorly water-soluble drugs. However, construction of in vitro and in vivo correlations (IVIVCs) for LBFs is quite challenging, owing to a complex in vivo processing of these formulations. In this paper, we start with a brief introduction on the gastrointestinal digestion of lipid/LBFs and its relation to enhanced oral drug absorption; based on the concept of IVIVCs, the current status of in vitro models to establish IVIVCs for LBFs is reviewed, while future perspectives in this field are discussed. In vitro tests, which facilitate the understanding and prediction of the in vivo performance of solid dosage forms, frequently fail to mimic the in vivo processing of LBFs, leading to inconsistent results. In vitro digestion models, which more closely simulate gastrointestinal physiology, are a more promising option. Despite some successes in IVIVC modeling, the accuracy and consistency of these models are yet to be validated, particularly for human data. A reliable IVIVC model can not only reduce the risk, time, and cost of formulation development but can also contribute to the formulation design and optimization, thus promoting the clinical translation of LBFs.
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Authors: Yana G. Najjar, Dustin McCurry, Huang Lin, Yan Lin, Yan Zang, Diwakar Davar, Arivarasan Karunamurthy, Joseph J. Drabick, Rogerio I. Neves, Lisa H. Butterfield, Marc S. Ernstoff, Igor Puzanov, Joseph J. Skitzki, Jennifer Bordeaux, IlaSri B. Summit, Jehovana O. Bender, Ju Young Kim, Beiru Chen, Ghanashyam Sarikonda, Anil Pahuja, Jennifer Tsau, Zeni Alfonso, Christian Laing, James F. Pingpank, Matthew P. Holtzman, Cindy Sander, Amy Rose, Hassane M. Zarour, John M. Kirkwood, Ahmad A. Tarhini
Journal: Clinical Cancer Research (2021)

Abstract Purpose: Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therapy in patients with resectable advanced melanoma. Patients and Methods: Patients with resectable stage III/IV melanoma were treated with concurrent pembrolizumab 200 mg i.v. every 3 weeks and HDI 20 MU/m2/day i.v., 5 days per week for 4 weeks, then 10 MU/m2/day subcutaneously 3 days per week for 2 weeks. Definitive surgery followed, as did adjuvant combination immunotherapy, completing a year of treatment. Primary endpoint was safety of the combination. Secondary endpoints included overall response rate (ORR), pathologic complete response (pCR), recurrence-free survival (RFS), and overall survival (OS). Blood samples for correlative studies were collected throughout. Tumor tissue was assessed by IHC and flow cytometry at baseline and at surgery. Results: A total of 31 patients were enrolled, and 30 were evaluable. At data cutoff (October 2, 2019), median follow-up for OS was 37.87 months (range, 33.2–43.47). Median OS and RFS were not reached. Radiographic ORR was 73.3% [95% confidence interval (CI): 55.5–85.8], with a 43% (95% CI: 27.3–60.1) pCR rate. None of the patients with a pCR have had a recurrence. HDI and pembrolizumab were discontinued in 73% and 43% of patients, respectively. Correlative analyses suggested that intratumoral PD-1/PD-L1 interaction and HLA-DR expression are associated with pCR (P = 0.002 and P = 0.008, respectively). Conclusions: Neoadjuvant concurrent HDI and pembrolizumab demonstrated promising clinical activity despite high rates of treatment discontinuation. pCR is a prognostic indicator. See related commentary by Menzies et al., p. 4133
P40.05 Current Status of a Smoking Cessation Supportive Program on Nurses' Interventions: A Single Institutional Experience
Authors: R. Kori, J. Ookawa, H. Sakai, H. Kimura, T. Miyazawa, H. Marushima, K. Kojima, M. Hara, H. Saji
Journal: Journal of Thoracic Oncology (2021)
Selecting Patients for Mammographic Evaluation Based on Breast Cancer Risk During the COVID-19 Pandemic
Authors: Sarah M. Friedewald, Dipti Gupta
Journal: JAMA Network Open (2021)

Diana L. Miglioretti, PhD; Michael C. S. Bissell, PhD; Karla Kerlikowske, MD; Diana S. M. Buist, PhD; Steven R. Cummings, MD; Louise M. Henderson, PhD; Tracy Onega, PhD; Ellen S. O'Meara, PhD; Garth H. Rauscher, PhD; Brian L. Sprague, PhD; Anna N. A. Tosteson, ScD; Karen J. Wernli, PhD; Janie M. Lee, MD; Christoph I. Lee, MD, MS
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort
Authors: Stephen A. Harrison, Samer Gawrieh, Katharine Roberts, Christopher J. Lisanti, Ryan B. Schwope, Katherine M. Cebe, Valerie Paradis, Pierre Bedossa, Jennifer M. Aldridge Whitehead, Aymeric Labourdette, Véronique Miette, Stefan Neubauer, Céline Fournier, Angelo H. Paredes, Naim Alkhouri
Journal: Journal of Hepatology (2021)